Shouxiangu brand Tiepi Fengdou granule enhances immune function on human body with TCM syndrome differentiating health care characteristic

注册号:

Registration number:

ITMCTR2200005695

最近更新日期:

Date of Last Refreshed on:

2022-03-12

注册时间:

Date of Registration:

2022-03-12

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

寿仙谷牌铁皮枫斗颗粒增强免疫力功能中医辨证保健特色的人体试食试验

Public title:

Shouxiangu brand Tiepi Fengdou granule enhances immune function on human body with TCM syndrome differentiating health care characteristic

注册题目简写:

English Acronym:

研究课题的正式科学名称:

寿仙谷牌铁皮枫斗颗粒增强免疫力功能中医辨证保健特色的人体试食试验

Scientific title:

Shouxiangu brand Tiepi Fengdou granule enhances immune function on human body with TCM syndrome differentiating health care characteristic

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2200057423 ; ChiMCTR2200005695

申请注册联系人:

张凤红

研究负责人:

杨溢

Applicant:

ZhangFenghong

Study leader:

YangYi

申请注册联系人电话:

Applicant telephone:

17694892628

研究负责人电话:

Study leader's telephone:

18622281699

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1826532184@qq.com

研究负责人电子邮件:

Study leader's E-mail:

yangyi@kaotg.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

天津市河东区华兴道21号福建大厦1904

研究负责人通讯地址:

天津市河东区华兴道21号福建大厦1901

Applicant address:

Room 1904,Fujian Building ,No.21 Huaxing Road, Hedong District, Tianjin, China

Study leader's address:

Room 1901,Fujian Building ,No.21 Huaxing Road, Hedong District, Tianjin, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

康奥科技集团有限公司

Applicant's institution:

Cobio Technology Group Limited

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013/8/26 0:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

康奥科技集团有限公司

Primary sponsor:

CoNo Technology Group

研究实施负责(组长)单位地址:

天津市河东区华兴道21号福建大厦1901-1907室

Primary sponsor's address:

Room1901-1907,Fujian Building,No.21 Huaxing Road, Hedong District, Tianjin, China 

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京中医药大学

具体地址:

北京市房山区良乡镇阳光南大街北京中医药大学

Institution
hospital:

Beijing University of Chinese Medicine

Address:

Beijing University of Chinese Medicine,Yangguang South Street, Liangxiang Town, Fangshan District, Beijing

经费或物资来源:

科技部国家重点研发计划项目(2018YFC1706800)

Source(s) of funding:

National key R & D program of the Ministry of science and technology(2018YFC1706800)

研究疾病:

免疫力低下

研究疾病代码:

Target disease:

hypoimmunity

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

连续入组

Sequential

研究所处阶段:

Study phase:

上市后药物

Post-marketing clinical trial

研究目的:

中药在我国有数千年的使用历史,将中药应用于保健食品是中国的特色。我国含中药成分的保健食品数量众多,但是目前我国中药成分保健食品没有使用指导原则,为了使中药成分保健食品发挥最大效果,本课题把辨证分型标准引入保健食品人体试食试验。探讨中医辨证应用于保健产品的重要性。开展已上市产品寿仙谷牌铁皮枫斗颗粒增强免疫力功能中医辨证保健特色的大样本人体试食试验,从功效(有效性)、安全性和经济性等方面比较寿仙谷牌铁皮枫斗颗粒对气阴两虚证型及非气阴两虚证型免疫力低下人群之间的差异。

Objectives of Study:

Traditional Chinese medicine has been used in China for thousands of years. The application of traditional Chinese medicine in health food is a Chinese characteristic. There are a large number of health food containing traditional Chinese medicine in China, but at present, there is no guiding principle for the use of traditional Chinese medicine health food in China. In order to maximize the effect of traditional Chinese medicine health food, this subject introduces the standard of syndrome differentiation into the human trial of health food and discusses the importance of applying syndrome differentiation of traditional Chinese medicine to health products.Carry out a large-scale human food trial of the marketed product Shouxiangu Brand Tiepi Fengdou Granules to enhance the immune function of TCM syndrome differentiation health care characteristics, and from the aspects of efficacy (effectiveness), safety and economy,compare the differences between Shouxiangu brand Tiepi Fengdou granules on Qi-Yin deficiency syndrome and non-Qi-Yin deficiency syndrome among immunocompromised people.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

①年龄18~65岁。 ②体质虚弱易生病者:满足其中1条即可。 A 感冒每年≥3次; B 支气管炎或肺炎 每年≥2次; C 易急性腹泻(乳糖、麦胶等食物不耐受除外)每年≥3次。 ③自愿签署知情同意书。

Inclusion criteria

① Age 18 ~ 65 years old. ② Physically weak and prone to disease: meet one of them. A cold ≥ 3 times a year; B bronchitis or pneumonia ≥ 2 times a year; C is prone to acute diarrhea (except lactose, gluten and other food intolerance) ≥ 3 times a year. ③ Voluntarily sign informed consent.

排除标准:

① 患免疫相关性疾病及肿瘤患者。 ② 因服用药物引起的免疫功能下降。 ③ 对该保健食品成分过敏者。 ④ 备孕、妊娠或哺乳期妇女。 ⑤ 合并严重心、脑、肝、肾、造血系统疾病,严重职业病及精神病受试者。 ⑥ 试食试验开始前4周内服用过影响免疫功能的产品,影响到对结果的判定者。

Exclusion criteria:

① Patients with immune related diseases and tumors. ② Decreased immune function caused by taking drugs. ③ Those who are allergic to the health food ingredients. ④ Pregnant, pregnant or lactating women. ⑤ Subjects with severe heart, brain, liver, kidney and hematopoietic system diseases, serious occupational diseases and psychosis. ⑥ Taking products that affect immune function within 4 weeks before the start of the food test affects the judge of the results.

研究实施时间:

Study execute time:

From 2022-03-01

To      2022-11-01

征募观察对象时间:

Recruiting time:

From 2022-04-01

To      2022-10-01

干预措施:

Interventions:

组别:

气阴两虚

样本量:

300

Group:

Deficiency of Qi and Yin

Sample size:

干预措施:

寿仙谷牌铁皮枫斗颗粒

干预措施代码:

Intervention:

Shouxiangu brand iron sheet Fengdou granule

Intervention code:

样本总量 Total sample size : 1000

研究实施地点:

Countries of recruitment
and research settings:

国家:

不适用

省(直辖市):

不适用

市(区县):

Country:

Not applicable

Province:

Not applicable

City:

单位(医院):

不适用

单位级别:

不适用

Institution/hospital:

Not applicable

Level of the institution:

Not applicable

测量指标:

Outcomes:

指标中文名:

中医证候观察评分表(气阴两虚证)

指标类型:

主要指标

Outcome:

TCM Syndromes Scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心率、心律、血压

指标类型:

主要指标

Outcome:

Heart rate, rhythm and blood pressure

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

症状积分量表

指标类型:

主要指标

Outcome:

Syndromes Scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

SF36量表

指标类型:

次要指标

Outcome:

SF36 scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

nothing

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 65
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男性

Male

随机方法(请说明由何人用什么方法产生随机序列):

非项目组成员通过计算机产生的随机数字表

Randomization Procedure (please state who generates the random number sequence and by what method):

Random numbers generated by Non project team member through computer

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Raw data will not be shared

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据管理委员会:

Data Managemen Committee:

No

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above